USANA Health Sciences (NYSE:USNA) Releases FY 2025 Earnings Guidance

Key Points

• USANA Health Sciences has provided FY 2025 earnings guidance with EPS projected at $1.73, surpassing the consensus estimate of $1.70, and revenue guidance of $920 million, slightly above the consensus of $919.6 million.
• The company's stock is down 1.0%, trading at $20.82, while analysts have downgraded their ratings on the stock from "strong-buy" to "hold."
• Hedge funds have increased their holdings in USANA, with notable increases from Lazard Asset Management and AQR Capital Management, reflecting growing institutional interest in the company.

USANA Health Sciences (NYSE:USNA - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 1.730-1.730 for the period, compared to the consensus estimate of 1.700. The company issued revenue guidance of $920.0 million-$920.0 million, compared to the consensus revenue estimate of $919.6 million.

USANA Health Sciences Stock Down 1.0%

Shares of NYSE:USNA traded down $0.22 during midday trading on Wednesday, reaching $20.82. The company's stock had a trading volume of 280,534 shares, compared to its average volume of 175,045. The firm has a market capitalization of $380.33 million, a PE ratio of 11.56, a P/E/G ratio of 1.01 and a beta of 0.61. USANA Health Sciences has a twelve month low of $19.88 and a twelve month high of $41.83. The stock has a fifty day moving average of $28.47 and a 200 day moving average of $29.01.

USANA Health Sciences (NYSE:USNA - Get Free Report) last released its quarterly earnings data on Thursday, October 9th. The company reported $0.56 earnings per share for the quarter. The firm had revenue of $200.22 million for the quarter. USANA Health Sciences had a net margin of 3.79% and a return on equity of 9.48%. USANA Health Sciences has set its Q3 2025 guidance at -0.150--0.150 EPS. Sell-side analysts anticipate that USANA Health Sciences will post 2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Zacks Research lowered shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 22nd. Wall Street Zen cut USANA Health Sciences from a "buy" rating to a "hold" rating in a report on Saturday, October 11th. Finally, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of USANA Health Sciences in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Reduce" and a consensus target price of $36.00.

Insider Buying and Selling at USANA Health Sciences

In other USANA Health Sciences news, insider David Mulham Mulham sold 3,515 shares of the stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $30.26, for a total transaction of $106,363.90. Following the transaction, the insider directly owned 9,260 shares of the company's stock, valued at $280,207.60. This trade represents a 27.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Gilbert A. Fuller sold 1,058 shares of the stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $29.10, for a total transaction of $30,787.80. The disclosure for this sale can be found here. Company insiders own 0.63% of the company's stock.

Hedge Funds Weigh In On USANA Health Sciences

Hedge funds and other institutional investors have recently modified their holdings of the business. Lazard Asset Management LLC lifted its stake in shares of USANA Health Sciences by 130.3% in the second quarter. Lazard Asset Management LLC now owns 23,201 shares of the company's stock worth $708,000 after buying an additional 13,128 shares in the last quarter. Empowered Funds LLC acquired a new stake in shares of USANA Health Sciences during the first quarter valued at about $687,000. AQR Capital Management LLC increased its position in shares of USANA Health Sciences by 82.8% during the first quarter. AQR Capital Management LLC now owns 21,845 shares of the company's stock valued at $589,000 after acquiring an additional 9,894 shares during the last quarter. Tidal Investments LLC increased its position in shares of USANA Health Sciences by 45.9% during the second quarter. Tidal Investments LLC now owns 16,906 shares of the company's stock valued at $516,000 after acquiring an additional 5,318 shares during the last quarter. Finally, Vident Advisory LLC acquired a new stake in shares of USANA Health Sciences during the second quarter valued at about $437,000. 54.25% of the stock is owned by hedge funds and other institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.